105 related articles for article (PubMed ID: 11032912)
1. Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.
Nielsen LL
Oncol Rep; 2000; 7(6):1191-6. PubMed ID: 11032912
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Nielsen LL; Shi B; Hajian G; Yaremko B; Lipari P; Ferrari E; Gurnani M; Malkowski M; Chen J; Bishop WR; Liu M
Cancer Res; 1999 Dec; 59(23):5896-901. PubMed ID: 10606231
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
6. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
[TBL] [Abstract][Full Text] [Related]
7. NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model.
Nielsen LL
Oncol Rep; 2000; 7(1):151-5. PubMed ID: 10601610
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
9. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Heise C; Lemmon M; Kirn D
Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251
[TBL] [Abstract][Full Text] [Related]
10. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
Mujoo K; Maneval DC; Anderson SC; Gutterman JU
Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881
[TBL] [Abstract][Full Text] [Related]
15. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
Oakley R; Phillips E; Hooper R; Wilson D; Partridge M
Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
17. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
18. Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
Nielsen LL; Gurnani M; Shi B; Terracina G; Johnson RC; Carroll J; Mathis JM; Hajian G
Cancer Res; 2000 Dec; 60(24):7066-74. PubMed ID: 11156413
[TBL] [Abstract][Full Text] [Related]
19. Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.
Atencio IA; Avanzini JB; Johnson D; Neuteboom S; Vaillancourt MT; Nielsen LL; Hajian G; Sutjipto S; Sugarman BJ; Philopena J; McAllister DL; Beltran JC; Nodelman M; Ramachandra M; Wills KN
Mol Ther; 2001 Jul; 4(1):5-12. PubMed ID: 11472100
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models.
Streck CJ; Dickson PV; Ng CY; Zhou J; Gray JT; Nathwani AC; Davidoff AM
Clin Cancer Res; 2005 Aug; 11(16):6020-9. PubMed ID: 16115947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
